Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model [PDF]
Antibiotics, 2022 Static concentration in vitro studies have demonstrated that fosfomycin- or sulbactam-based combinations may be efficacious against carbapenem-resistant Acinetobacter baumannii (CRAB).
Sazlyna Mohd Sazlly Lim +5 more
doaj +2 more sources
Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant Acinetobacter baumannii Infections—A Meta-Analysis [PDF]
AntibioticsThe addition of sulbactam restores the complete range of cefoperazone activity against bacteria and extends its spectrum of action to include the Acinetobacter species.
Chienhsiu Huang, Lichen Lin, Sufang Kuo
doaj +2 more sources
Semi-mechanistic PK/PD modelling of fosfomycin and sulbactam combination against carbapenem-resistant Acinetobacter baumannii. [PDF]
, 2021 Due to limited treatment options for carbapenem-resistant Acinetobacter baumannii (CR-AB) infections, antibiotic combinations are now considered potential treatments for CR-AB.
Heffernan, AJ +3 more
core +1 more source
Sulbactam/Durlobactam: First Approval [PDF]
, 2023 Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Susan Keam (4873372)
core +1 more source
Table_1_Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates.docx [PDF]
, 2022 Carbapenems are commonly used to treat infections caused by multidrug-resistant (MDR) bacteria. Unfortunately, carbapenem resistance is increasingly reported in many gram-negative bacteria, especially Acinetobacter baumannii.
Grace Ra (13024683) +9 more
core +1 more source
Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii [PDF]
, 2023 Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β ...
Pournaras, Spyros +4 more
core +6 more sources
CSE (Ceftriaxone+ Sulbactam+ Disodium Edta): A Possible Solution to the Global Antimicrobial Resistance Pandemic [PDF]
, 2020 The menace of multidrug resistance among bacterial infections is an issue of global public health. Treatment of these superbugs with first line antibiotics is associated with significant treatment failure leading to increased mortality and morbidity ...
Shalini Upadhyay +3 more
core +1 more source
DataSheet_1_Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption.doc [PDF]
, 2021 BackgroundABO blood type incompatibility hemolytic disease of newborn (ABO-HDN) and drug-induced immune hemolytic anemia (DIIHA) due to non-immunologic protein adsorption (NIPA) mainly cause extravascular hemolysis.
Yuanjun Wu (11865839) +6 more
core +1 more source
Frontiers in Microbiology, 2022 Amikacin and polymyxins as monotherapies are ineffective against multidrug-resistant Acinetobacter baumannii at the clinical dose. When polymyxins, aminoglycosides, and sulbactam are co-administered, the combinations exhibit in vitro synergistic ...
Shixing Zhu +11 more
doaj +1 more source
Cefotaxime/sulbactam: clinical and pharmacological characteristics [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2019 The recently approved cefotaxime/sulbactam, combination of third-generation cephalosporin (cefotaxime) and beta-lactamase inhibitor (sulbactam), can combat resistance mechanisms associated with the production of serine beta-lactamases, including some ...
Ortenberg E.A., Golub A.V.
doaj +1 more source